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ense.Abstract Background: Nuclear unrest is a term applied to Wilms’ tumors (WT) that show nuclear
abnormalities close to anaplasia but without abnormal mitoses. p53 is claimed to be associated with
anaplasia and poor prognosis. This study was undertaken to evaluate the clinical signiﬁcance of
nuclear unrest and p53 immunostaining in Wilms’ tumor.
Material and methods: This is a retrospective study of 63 patients who presented at NCI with
Wilms’ tumors, and underwent preoperative chemotherapy followed by nephrectomy. Histopatho-
logic assessment and p53 immunohistochemistry were done.
Results: WT with nuclear unrest grade III closely resembled anaplastic tumors and both of them
(group 1) constituted 19% of cases. Group 1 constituted 29% of cases showing blastema dominant
morphology compared to 9.4% of cases without blastema dominant morphology with signiﬁcant
statistical difference (p= 0.047). Almost 83% of cases that achieved 1st complete remission were
stages I, II and III, while 17% were stages IV and V with signiﬁcant statistical difference
(p< 0.001). Stage affected the 3-year relapse-free-survival (RFS) signiﬁcantly (p= 0.014) as it
was more in stages I, II and III than in stages IV and V (75.4% versus 50%). Blastema dominant
morphology and high risk state signiﬁcantly lowered the 3-year overall survival (OS) into 54.8% in
comparison to 80.9% for cases with non-blastema dominant morphology (p= 0.042). Regarding
p53 immunohistochemistry, group 1 tumors showed positive p53 more than group 2 with signiﬁcantrtment of Pathology, Surgical






32 A. Salama, A. Kamelstatistical difference (p= 0.014). p53 Positive immunostaining was signiﬁcantly associated with
high risk nephroblastoma (p= 0.004).
Conclusion: Tumor stage and blastema dominant morphology are potent prognostic factors. p53 is
linked to blastema dominant morphology. WT with nuclear unrest grade III closely resembles
anaplastic WT. It may be appropriate to group tumors with nuclear unrest grade III with anaplastic
histology regarding treatment stratiﬁcation.
Open access under CC BY-NC-ND license.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.Introduction
Renal tumors are the ﬁfth most common tumor in the ﬁrst 15
years of life comprising 7%, coming after leukemia, brain
cancer, soft tissue sarcomas and non-Hodgkin lymphoma
(NHL). Wilms’ tumor is by far the most common pediatric
renal tumor (85% of cases) [1]. Histologic classiﬁcation is
the most potent prognostic indicator for patients with Wilms’
tumor as stated by the ﬁrst National Wilms’ Tumor Study
Group (NWTSG-1) which implies treating Wilms’ tumors by
surgery ﬁrst followed by, if necessary, postoperative chemo-
therapy and/or radiotherapy. This study classiﬁed Wilms’
tumor into favorable histology and anaplastic Wilms’ tumor,
the latter is associated with adverse outcome. Anaplasia is
deﬁned by the presence of large nuclear size, hyperchromasia
and irregular mitotic ﬁgures [2].
On the other hand, preoperative chemotherapy has been an
essential part of the International Society of Pediatric
Oncology (SIOP) treatment strategy since its ﬁrst trials, and
so, its histologic classiﬁcation differs as it reﬂects chemother-
apy-induced changes. The revised SIOP histologic classiﬁca-
tion divides Wilms’ tumor into three risk groups: (a) low risk
(completely necrotic nephroblastoma and cystically partially
differentiated nephroblastoma); (b) intermediate risk (regres-
sive, epithelial, stromal, mixed, or focal anaplastic nephroblas-
toma); and (3) high risk (blastemal and diffuse anaplastic
nephroblastoma) [3,4].
Some Wilms’ tumors within the favorable histology cate-
gory show disturbing nuclear enlargement, cytologic atypia,
and histologic disarray that do not quite attain the degree of
severity required for a designation of anaplasia, what is known
as nuclear unrest [5]. Because the clinical signiﬁcance of nucle-
ar unrest has not been studied systematically, the appropriate
treatment for patients with such tumors is unclear, making
patients having tumors with nuclear unrest to be currently
treated by regimens used for patients with tumors showing
favorable histology, regardless of the cytologic similarities
between tumors with nuclear unrest and anaplastic tumors
which provide a source of anxiety for pathologists as well as
for clinicians [6].
In addition, although several studies have shown that
detection of p53 by immunostaining is strongly associated with
anaplasia in Wilms’ tumor, yet the association with nuclear
unrest has not been studied enough [7]. It is well known that a
functional p53 protein has been linked to cell cycle checkpoint
control, and the presence of p53 mutations may contribute to
the increased DNA content and the irregular mitotic ﬁgures
observed in anaplastic Wilms’ tumor [8]. Moreover, the impor-
tance of p53 in directing cells with DNA damage into an apop-
totic pathwaymay provide amolecular basis for the insensitivity
of anaplastic tumors to therapeutic intervention [9].We aim at evaluation of p53 expression and nuclear unrest
in Wilms’ tumor through a retrospective study to elucidate
their clinical signiﬁcance.
Patients and methods
This retrospective study was initially conducted on all patients
presenting to the Pediatric Oncology Clinic, National Cancer
Institute (NCI), Cairo University from January 1, 2001 to
December 31, 2008 and diagnosed as having Wilms’ tumor.
Of 132 patients, 42 patients were excluded because their
parafﬁn blocks were not available (nephrectomies were done
outside our institute). Ten cases were excluded because of
inadequate sampling and unavailable clinical data. Seventeen
cases were not included because of extensive necrosis which
hindered immunohistochemical study. Our study was limited
to 63 patients only to justify the adequacy of tumor sampling
by examination of at least four representative slides for each
case.
According to the SIOP WT protocol, children were treated
with preoperative chemotherapy then followed by surgery and
further chemotherapy with or without radiotherapy, if neces-
sary. The tumors were histologically classiﬁed into three risk
groups: (a) low risk (cystic partially differentiated nephroblas-
toma), (b) intermediate risk (regressive, epithelial, stromal, or
mixed), and (c) high risk (blastemal or diffuse anaplasia) [4].
Complete remission (CR) was achieved by complete disappear-
ance of the disease (primary tumor and its metastasis if
present), whether by surgery alone or by surgery followed by
chemotherapy and/or radiotherapy. It could be either ﬁrst
after tumor diagnosis or second after occurrence of relapse.
A diagnosis of anaplasia was made according to NWTS
Group criteria: (1) an increase in greatest nuclear dimension
at least three times that of adjacent nuclei of the same cell type;
(2) hyperchromasia of the enlarged nuclei; and (3) the presence
of abnormal multipolar mitotic ﬁgures. The criteria used to
identify tumors with nuclear unrest and grade them were:
grade 1 unrest reﬂects minimal disorder with nuclear diameter
approximating that of RBC, while grade 3 connotes striking
cytologic atypia and histologic disarray without multipolar mi-
totic ﬁgures and just short of anaplasia. Grade 2 is intermedi-
ate [10]. Tumor stage was determined from the clinical ﬁles
using SIOP WT 2001 staging criteria [11].
Four hematoxylin and eosin slides of each case were pre-
pared for proper evaluation of tumor type, chemotherapy in-
duced changes and assessment of anaplasia.
Immunohistochemical analysis of p53 was performed on
4 lm thick, formalin ﬁxed, parafﬁn embedded tissue sections
which were treated with heat in a water bath (95–99 C) for
20 min. Target retrieval involves immersion of tissue sections
in a pre-heated citrate buffer at pH 9 for 30 min. The mouse
Nuclear unrest & p53 in Wilms’ tumor 33monoclonal antihuman p53 antibody (DO-7 ready to use;
Dako, Denmark) was applied and incubated overnight. Slides
were developed with an avidin–biotin–peroxidase complex
technique [12]. Positive controls were done using sections from
known positive p53 breast carcinoma cases.
For assessment of p53 immunostaining, tumor cells with
clearly brown reaction in the nuclei were counted by monitor-
ing at least 1000 tumor cells from more than ﬁve high power
ﬁelds where positive cells were present at relatively uniform
density, and the percentage was then calculated. The numbers
of immunopositive cells were counted and the case was catego-
rized as negative when none or only a few (<5%) cells on the
whole slide showed a weak staining [13].
Data were analyzed using the SPSS statistical package.
Numerical data were expressed as median, maximum and min-
imum. Qualitative data were expressed as frequency and per-
centage. The chi-square test and Fisher’s exact test were used
to examine the relation between qualitative variables. Survival
analysis was carried out using the Kaplan–Meier method and
presented as cumulative survival rates. Comparison between
two survival curves was done using the log-rank test. Probabil-
ity (p-value) equal or less than 0.05 was considered signiﬁcant,
and if less than 0.001, highly signiﬁcant. Relapse-free survival
(RFS) was calculated only for patients who achieved complete
remission (CR) [14]. To study the independent effect of each
signiﬁcant factor on RFS and OS, signiﬁcant factors were
entered into a stepwise Cox proportional hazards model.
Results
Patient characteristics
Table 1 summarizes the clinical characteristics of the 63
patients who were included in the study as well as associationsTable 1 Histology in relation to patient characteristics.






63 years 34 5 (14.7) 29 (85.3) 0.342
>3 years 29 7 (24.1) 22 (75.9)
Gender
Male 31 7 (22.6) 24 (77.4) 0.482
Female 32 5 (15.6) 27 (84.4)
Stage
I, II and III 48 9 (18.8) 39(81.2) 0.767
IV and V 15 3 (20) 12 (80)
Morphologic subtype
Blastema dominant 31 9 (29) 22 (71) 0.047
Not blastema dominant 32 3 (9.4) 29 (90.6)
Risk
High 31 9 (29) 22 (71) 0.047
Intermediate and low 32 3 (9.4) 29 (90.6)
1st CR
Yes 58 11 (19) 47 (81) 0.955
No 5 1 (20) 4 (80)
Histology includes Group 1: Nuclear unrest grade III and anaplasia
and Group 2: Nuclear unrest grades I and II and favorable.between clinical characteristics and histopathologic features.
Patient ages at time of diagnosis ranged from 0.3 to10 years
with a median age 3 years. Males and females were almost
equally affected (49.2% and 50.8%, respectively). Tumors
were classiﬁed histologically as favorable histology (34.9% of
cases), unfavorable histology (6.4%), and tumors with nuclear
unrest (58.7%) (Fig. 1). The latter showed grade I unrest in
37.84%, grade II unrest in 40.54%, and grade III unrest in
21.62%.
Histopathologically, the only difference between tumors
with anaplasia and tumors with grade III nuclear unrest is
detection of multipolar mitosis. The latter necessitates
meticulous microscopic examination of multiple sections taken
from each centimeter of maximal tumor diameter. This was
not possible in this study being retrospective. Moreover, due
to the small number of tumors with anaplasia, combination
of those cases with tumors showing grade III unrest was done
and named as Group 1. The rest of cases, tumors with favor-
able histology and tumors with nuclear unrest grade I and
II, were also combined together and named as Group 2. Group
1 constituted 19% of all cases. Group 1 constituted 29% of
cases that showed blastema dominant morphology compared
to 9.4% of cases without blastema dominant morphology with
signiﬁcant statistical difference (p= 0.047). Consequently,
group 1 constituted 29% of cases carrying a high risk state
compared to 9.4% of cases with low and intermediate risk with
signiﬁcant statistical difference (p= 0.047). It appeared that
age (p= 0.342), gender (p= 0.482), stage (p= 0.767), and
achievement of 1st CR (p= 0.955) did not associate with
tumor histology signiﬁcantly.
Morphologic subtypes included blastema dominant mor-
phology (49.2%), mixed (27%), epithelial dominant (7.9%),
stroma dominant (7.9%), regressive (6.3%), and cystically
partially differentiated nephroblastoma (CPDN) (1.6%).
Consequently, high risk patients constituted 49.2%, intermedi-
ate risk patients were 49.2%, and low risk patients were 1.6%
of our patient population.
Table 2 illustrates tumor stages which included stage I
(22.2%), II (12.7%), III (41.3%), IV (14.3%), and V (9.5%).
All cases of stage V had having lung metastases. For statistical
reasons, combination of stages I, II, and III was done
(representing tumors that were localized abdominally), and
stages IV and V were also combined together (representing
tumors with distant spread). Advanced stage (IV and V) con-
stituted 31% of children older than 3 years in contrast to
17.6% of children younger than or aged 3 years with signiﬁ-
cant statistical difference (p= 0.047). About 37.5% of female
children presented with advanced stage in comparison to
9.7% of male children with signiﬁcant statistical difference
(p= 0.01). No signiﬁcant association was detected between
stage and either tumor histology (p= 0.767), morphologic
subtype (p= 0.338) or risk state (p= 0.338).
p53 Immunohistochemistry analysis
p53 was positive in 38 cases (60.3%) and staining was seen in
blastema cells and tubules. The stroma was invariably nega-
tive. The majority of tumors of group 2 showed few scattered
tumor cells with weak nuclear staining, while diffuse strong
staining was achieved in tumors of group 1 (Fig. 2). Histology
was signiﬁcantly associated with p53 immunoreaction as the
majority of group 1 (91.7%) showed positive p53 in contrast
Figure 1 (A) Wilms tumor with favorable histology. (B) Wilms tumor with nuclear unrest grade III. (C) Wilms tumor with anaplasia.
Note the multipolar mitotic ﬁgure (arrow). (D) Higher magniﬁcation of the previous case to illustrate multipolar mitotic ﬁgure.
(hematoxylin and eosin; original magniﬁcation ·400 in A–C, ·1000 in D).
Table 2 Stage in relation to patient characteristics.
Characteristics No. Stages I, II and III n (%) Stages IV and V n (%) p-Value
Age
63 years 34 28 (82.4) 6 (17.6) 0.047
>3 years 29 20 (69) 9 (31)
Gender
Male 31 28 (90.3) 3 (9.7) 0.01
Female 32 20 (62.5) 12 (37.5)
Histology
Group 1 12 9 (75) 3 (25) 0.767
Group 2 51 39 (76.5) 12 (23.5)
Morphologic subtype
Blastema dominant 31 22 (71) 9 (29) 0.338
Not blastema dominant 32 26 (81.3) 6 (18.7)
Risk
High 31 22 (71) 9 (29) 0.338
Intermediate and low 32 26 (81.3) 6 (18.7)
1st CR
Yes 58 48 (82.8) 10 (17.2) <0.001
No 5 0 5 (100)
34 A. Salama, A. Kamelto 52.9% of group 2 (p= 0.014). p53 Positive immunostaining
was signiﬁcantly more prevalent in tumors showing blastema
dominant morphology (80.6%) than other tumors (40.6%)
(p= 0.001), and subsequently, p53 positive immunostaining
was signiﬁcantly associated with high risk nephroblastoma
(p= 0.001). No signiﬁcant association was obtained between
p53 immunostaining and either age (p= 0.07), gender(p= 0.382), stage (p= 0.565), or achievement of 1st CR
(p= 0.988) (Table 3).
Outcome analysis
Among 63 patients, the median follow-up was 34.9 months
(range, 2.2–111.5 months). Complete remission was achieved
Figure 2 (A and B) Typical diffuse pattern of strong p53 staining in anaplastic Wilms tumor and tumor with grade III nuclear unrest,
respectively. (C) p53 staining in grade II nuclear unrest. (D) p53 was seen in blastema and epithelium components. (anti-p53
immunostaining with hematoxylin counterstain; original magniﬁcation ·400).
Table 3 p53 Immunostaining in relation to prognostic factors.
Characteristics No. Positive p53 n (%) Negative p53 n (%) p-Value
Age
63 years 34 17 (50) 17 (50) 0.07
>3 years 29 21 (72.4) 8 (27.6)
Gender
Male 31 17 (54.8) 14 (45.2) 0.382
Female 32 21 (65.6) 11 (34.4)
Stage
I, II and III 48 28 (58.3) 20 (41.7) 0.565
IV and V 15 10 (26.3) 5 (20)
Histology
Group 1 12 11 (91.7) 1 (8.3) 0.014
Group 2 51 27 (52.9) 24 (47.1)
Morphologic subtype
Blastema dominant 31 25 (80.6) 6 (19.4) 0.001
Not blastema dominant 32 13 (40.6) 19 (59.4)
Risk
High 31 25 (80.6) 6 (19.4) 0.001
Intermediate and low 32 13 (40.6) 19 (59.4)
1st CR
Yes 58 35 (60.3) 23 (39.7) 0.988
No 5 3 (60) 2 (40)
Nuclear unrest & p53 in Wilms’ tumor 35in 58 patients (92.1% of cases). Almost 83% of cases that
achieved 1st complete remission were stages I, II and III, while
17.2% were stages IV and V with a highly signiﬁcant statistical
difference (P< 0.001).
The three-year relapse-free-survival (RFS) was 65%.
Relapse sites included local recurrence in 6 patients, distantmetastases (lung, liver, brain and bone) in 6 patients, and both
local and distant recurrence in 9 patients. Lung metastasis
occurred in 13 cases while abdominal recurrence occurred in
15 cases. The effect of age, gender, stage, histology, morpho-
logic subtype, risk and p53 on 3-year RFS is shown in Table
4. Stage affected 3-year RFS signiﬁcantly (Fig. 3). The 3-year
Table 4 Relapse-free-survival (RFS) in relation to prognostic
factors.
Characteristics Number of cases 3-year RFS (%) p-Value
Total 58 65.0
Age
63 years 32 75.9
>3 years 26 48.1 0.225
Gender
Male 30 82.5
Female 28 56.5 0.010
Stage
I, II and III 48 75.4
IV and V 10 50.0 0.014
Histology
Group 1 11 53.0
Group 2 47 74.5 0.252
Morphologic subtype






Low and intermediate 30 83.1 0.081
P53
Positive 35 71.9
Negative 23 69.3 0.849
Table 5 Overall survival (OS) in relation to prognostic
factors.
Characteristics Number of cases 3-year OS (%) p-Value
Total 63 68.5
Age
63 years 34 75.8
>3 years 29 59.8 0.219
Gender
Male 31 82.9
Female 32 54.4 0.011
Stage
I, II and III 48 77.8
IV and V 15 40.0 0.002
Histology
Group 1 12 58.3
Group 2 51 71.3 0.193
Morphologic subtype






Low and intermediate 32 80.9 0.042
P53
Positive 38 69.8
Negative 25 66.8 0.783
36 A. Salama, A. KamelRFS was more in stages I, II and III than in stages IV and V
(75.4% versus 50%). Blastema dominant morphology and
high risk state tended to lower the 3-year RFS into 54.2%
compared to 83.1% for other cases, however the difference
could not attain statistical signiﬁcance (p= 0.081). No signif-
icant association was obtained between 3-year RFS and either
age (p= 0.225), histology (0.252) or p53 (p= 0.849).
The three-year overall survival (OS) was 68.5% (Table 5).
Advanced stage (IV and V) signiﬁcantly lowered 3-year OS
into 40% in contrast to 77.8% for stages I, II and IIIFigure 3 Three-year RFS in patients w(Fig. 4). Blastema dominant morphology and high risk state
were signiﬁcantly associated with worse 3-year OS (Fig. 5).
No signiﬁcant association was obtained between 3-year OS
and either age (p= 0.219), histology or p53 overexpression
(p= 0.783).
Multivariate analysis was done using the Cox proportional
hazards model for the study of the effect of prognostic factors
on relapse free survival and overall survival as shown in
Table 6. Tumor stage was the only independent signiﬁcant
prognostic factor. The chance of relapse among stages IVith Wilms’ tumor according to stage.
Figure 4 Three-year OS in patients with Wilms’ tumor according to stage.
Table 6 Cox proportional hazards model for effect of prognostic factors on relapse-free-survival and overall survival.
B SE p-Value HR 95.0% CI for HR
Lower Upper
RFS Stage 1.116 0.464 0.016 3.05 1.23 7.58
OS Stage 1.343 0.461 0.004 3.83 1.55 9.45
RFS, relapse-free-survival; OS, overall survival; B, regression coefﬁcient; SE, standard error, HR, hazard ratio.
Figure 5 Three-year OS in patients with Wilms’ tumor according to morphologic subtype.
Nuclear unrest & p53 in Wilms’ tumor 37and V was 3 times more than others (p= 0.016, 95% CI for
HR 1.23–7.58). The probability of death among stages IV
and V was 3.8 times more than others (p= 0.004, 95% CI
for HR 1.55–9.45).Discussion
Wilms’ tumor is the most common primary renal malignancy
of childhood. The median age at diagnosis in our study was
36 months, which is comparable to a Turkish study by Yildizet al. [15]. In our study, stage I constituted 22.2% of cases,
stage II (12.7% of cases), stage III (41.3% of cases), stage IV
(14.3% of cases) and stage V (9.5%). Less advanced stages
were reported by other Western and Asian studies. In the
2nd UKCCS [16], NWTS [17] and SIOP [18], stage I accounted
for 34%, 47% and 61%, respectively. In the Taiwanese [19],
Turkish [15] and 3rd NWTS [20], stage IV accounted for only
6.8%, 9% and 10%, respectively. We also noticed that female
patients presented with advanced stage (IV and V) more than
males (80% versus 20%, respectively). This may reﬂect lack of
awareness among the mothers of our patients and reluctant
38 A. Salama, A. Kamelattitude toward female children more than males and diminu-
tion of medical services in the rural areas of our country.
Wilms’ tumor with nuclear unrest has morphologic features
that are intermediate between tumors with favorable histology
and anaplastic tumors. The signiﬁcance of this morphologic
change is unclear, and it is uncertain whether patients who
have these tumors necessitate more aggressive treatment than
the treatment provided for patients who have tumors with
favorable histology. We noticed that Wilms’ tumor with nucle-
ar unrest grade III closely resembled tumors with anaplastic
histology (constituted group 1) than tumors with favorable his-
tology or tumors with nuclear unrest grade I and II (consti-
tuted group 2) regarding blastema dominant morphology
and high risk state. Group 1 constituted 29% of cases showing
blastema dominant morphology and high risk state compared
to 9.4% of cases without blastema dominant morphology and
with low and intermediate risk with signiﬁcant statistical
difference (p= 0.047). This enforces our suggestion that
tumors with anaplasia and tumors with nuclear unrest grade
III are close to each other biologically sharing blastema dom-
inant morphology which is known to carry a high risk state.
However, there was no signiﬁcant difference between tumors
of group 1 and tumors of group 2 regarding age, gender, stage,
and achievement of 1st CR. This was in agreement to what was
reported by Hill et al. [6] who observed that Wilms’ tumors
with nuclear unrest more closely resembled tumors with favor-
able histology than tumors with anaplastic histology with
regard to the clinical features of stage and patient age at pre-
sentation. But Hill et al. studied all cases of nuclear unrest
as one category and did not analyze each grade separately.
Moreover, they did not analyze the association between nucle-
ar unrest grades and each of blastema dominant morphology,
risk state and p53 overexpression.
Our study demonstrated that blastema dominant morphol-
ogy was the most prevalent morphologic subtype (49.2%)
which was higher than what was documented by Weirich
et al. [21] who reported that in the immediately operated WTs
the most common subtype was mixed (45.1%), followed by
blastemal (39.4%) and epithelial predominant (15.5%),
whereas in tumors that received preoperative chemotherapy,
the most common type was regressive (37.6%), followed by
mixed (29.4%), stromal (14%), blastemal (9.3%) and epithelial
predominant (3.1%); 6.6% of tumors were completely necrotic.
In our study, positive p53 immunostaining was signiﬁcantly
more prevalent in group 1 than in group 2 (91.7% versus
52.9%, respectively). This highlights the resemblance of nucle-
ar unrest grade III to anaplasia. Moreover, blastema dominant
morphology was signiﬁcantly associated with prevalent p53
overexpression. p53 Overexpression usually reﬂects p53 gene
mutation resulting in increased DNA content, accumulation
of genetic damage with failure in directing cells with DNA
damage into an apoptotic pathway culminating in the insensi-
tivity to therapeutic intervention. This could explain why
blastema dominant morphology denotes high risk state as
documented by the revised SIOP histologic classiﬁcation of
Wilms’ tumors [9].
Achievement of 1st CR occurred in 92.1% of cases and was
signiﬁcantly associated with stage. Almost 83% of cases that
achieved 1st complete remission were stages I, II and III while
17% were stages IV and V with a highly signiﬁcant statistical
difference (P< 0.001). This highlights the strength of stage as
a prognostic factor in Wilms’ tumor.Relapse-free-survival (RFS) at 3 years in our study (65%)
was lower than what was reported by the 9th SIOP [22] study
which showed a 5-year RFS of 82%. This could be explained
by the advanced stage at presentation in our patients and dom-
inance of blastema morphology. On the other hand, our 3-year
RFS was higher than what was reported by Abd El-Aal et al.
[23] who found that the 4-year RFS was 58%. This may be
attributed to the improved treatment results in our cases. Stage
affected 3-year RFS signiﬁcantly as it was more in stages I, II
and III than in stages IV and V (75.4% versus 50%). These re-
sults coincide with those reported by Hill et al. [6] and Abd El-
Aal et al. [23] who concluded that stage signiﬁcantly affected
survival. This again highlights the role of stage in predicting
the prognosis of patients with Wilms’ tumor. In our study,
there was a tendency for lower 3-year RFS in cases with blas-
tema dominant morphology than others, but unfortunately the
difference could not attain statistical signiﬁcance (p= 0.081).
This could be attributed to the small number of patients, espe-
cially that p-value is close to the signiﬁcant level.
Overall survival (OS) at 3 years in our study was 68.5%,
which was lower than other Western studies. In the 2nd
UKCCS and the 9th SIOP study, the 5-year OS were 83%
and 87%, respectively. This reﬂects their better local and met-
astatic control with proper supportive care, beside dominance
of advanced stage in our cases augmented by poor perfor-
mance and nutritional status.
Advanced stage (IV and V) signiﬁcantly lowered the 3-year
OS into 40% of our patients in contrast to 77.8% for stages I,
II and III (p= 0.002). This is in agreement with Abd El-Aal
et al. [23] who reported that stage signiﬁcantly affected survival
and this reinforces the role of stage as a potent prognostic fac-
tor with special emphasis on patients with abdominal disease
as they still have a better chance than others who have distant
metastatic disease.
Our study demonstrated the 3-year OS for cases with blas-
tema dominant morphology to be 54.8% compared to 80.9%
for cases with non blastema dominant morphology with signif-
icant difference (p= 0.042). Our ﬁgure for patients with non
blastema dominant morphology is comparable to that re-
ported by the SIOP 93-01 (90%) [18] while that obtained with
blastema dominant morphology is lower (79%). This again
emphasizes their better supportive care especially during inten-
siﬁed chemotherapeutic regimens.
It was noticed that 3-year RFS and 3-year OS in females
were shorter than in males with signiﬁcant statistical difference.
This could be explained by the prevalence of advanced stage (IV
and V) in females rather than the gender itself as bymultivariate
analysis using the Cox proportional hazards model for effect of
prognostic factors on relapse free survival and overall survival,
stage was the only independent signiﬁcant prognostic factor.
The chance of relapse among stages IV and V was 3 times more
than others (p= 0.016, 95% CI for HR 1.23–7.58). The prob-
ability of death among stages IV and V was 3.8 times more than
others (p= 0.004, 95% CI for HR 1.55–9.45).Conclusion
The morphologic response to preoperative chemotherapy is
considered as an in vivo test for effectiveness of these drugs
which is very important in planning the postoperative treat-
ment plan.
Nuclear unrest & p53 in Wilms’ tumor 39Tumor stage and morphologic subtypes were found to be
the most important determinants of prognosis of Wilms’
tumor in our study and they deserve priority in precise and
meticulous sampling of the nephrectomy specimen for proper
assessment of stage and assessment of chemotherapy induced
changes for better categorization of the patients regarding post
operative treatment. This also helps in deﬁning anaplasia and
various grades of nuclear unrest in larger number of patients
for further studies to clarify exactly the weight of nuclear
unrest in Wilms’ tumor.
Nuclear unrest represents an intermediary in the spectrum
from favorable histology to anaplastic histology and nuclear
unrest grade III is a very close station to anaplastic morphol-
ogy especially if associated with p53 overexpression. p53 is
linked to blastema dominant morphology, nuclear unrest
grade III and anaplastic histology. Blastema dominant mor-
phology is associated with poor survival. More studies are
needed to conﬁrm grouping of grade III nuclear unrest with
anaplastic histology for treatment purposes as it may be
appropriate to design a future study for treatment of Wilms’
tumor with special consideration to patients having blastema
dominant morphology, nuclear unrest grade III and p53 over-
expression in a similar way to patients having tumors with
anaplastic histology.
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